Outdoor risky play and health-related outcomes in children aged 3-12 years: A mixed-methods systematic review.

PLoS OneOct 26, 2026 (epub)

Rachel Ramsden, Alethea G Jerebine, Gemma Brailey et al.

✦ AI-curated · Sources linked

In 30 seconds

This mixed-methods systematic review synthesised evidence on outdoor risky play and health outcomes in children aged 3–12 years. It included 74 studies: 48 quantitative, 19 qualitative and 7 mixed-methods. General risky play and environments that support it were positively associated with outcomes in physical, mental health and well-being, social, cognitive, and risk competence domains. Independent mobility was positively associated with physical activity, while rough-and-tumble play findings were inconsistent except for a negative association with aggression. Overall evidence quality was low-to-moderate, limiting firm conclusions.

Key findings

  • The review included 74 studies: 48 quantitative, 19 qualitative and 7 mixed-methods.
  • General risky play and supportive environments were positively associated with outcomes across five health domains.
  • Independent mobility was positively associated with physical activity; evidence for other health domains was insufficient.
  • Rough-and-tumble play evidence was inconsistent, except for a negative association with aggression.

Why it matters

The review brings together evidence across several dimensions of child health and suggests that outdoor risky play may be associated with beneficial outcomes, rather than being relevant only to injury risk. However, the low-to-moderate evidence quality and limited studies in some domains mean these associations should be interpreted cautiously. The findings help identify where stronger research is needed to clarify potential benefits and harms.

What to keep in mind

The authors report low-to-moderate overall evidence quality and too few studies in some health domains to support firm conclusions.

Source

Published in PLoS One. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.